EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases.
BACKGROUND
(32)P phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom (32)P is the most optimal treatment option, an assertion supported by two large studies with long follow-up.


OBJECTIVE
The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for (32)P phosphate therapy.
Tennvall
Jan
J
Department of Oncology, Lund University Hospital, 221 85 Lund, Sweden. Jan.Tennvall@med.lu.se
Brans
Boudewijn
B
D000328:Adult; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000532:radiotherapy*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D011786:Quality Control; D011874:Radiometry; D019275:Radiopharmaceuticals; D011878:Radiotherapy / Q000379:methods* / Q000592:standards*; D013920:Thrombocythemia, Essential / Q000532:radiotherapy*
D010761:Phosphorus Radioisotopes; D019275:Radiopharmaceuticals